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Abstract
Hypertension complicates up to 10% of pregnancies worldwide. Pregnancy hypertension is defined as systolic blood pressure (BP) equal to or greater than 140 mm Hg or diastolic BP equal to or greater than 90 mm Hg, usually on the basis of measurements in office/clinic settings and using various BP devices. Hypertensive disorders of pregnancy are classified into (1) chronic hypertension diagnosed before pregnancy or before 20 weeks' gestation, (2) gestational hypertension diagnosed at equal to or greater than 20 weeks, or (3) preeclampsia, defined restrictively as gestational hypertension with proteinuria or broadly as gestational hypertension with proteinuria or an end-organ manifestation consistent with preeclampsia. Absolute BP values equal to or greater than 140/90 mm Hg are associated with increased maternal and perinatal risks, particularly with preeclampsia. This review focuses on antihypertensive therapy of hypertensive disorders of pregnancy as a specific management strategy. Underpinning this therapy is the need for accurate measurement of BP, agreed-upon classification of pregnancy hypertension, agreed-upon BP thresholds for enhanced surveillance and antihypertensive treatment, and collaborative teamwork in management. Challenges relate to the methodology of studies on which care is based, as well as aspects of the care itself, particularly the unregulated use of home BP monitoring. Pitfalls include the unsubstantiated belief that nifedipine and magnesium sulfate cannot be used together and the perception that severe hypertension and nonsevere hypertension are separate entities rather than lying along a spectrum of BP values. The following must be addressed by future research: guidance for nuanced care as women transition between severe and nonsevere hypertension, personalized antihypertensive therapy, and incorporation of women's values into research priorities and clinical practice when antihypertensive care is chosen. H ypertension complicates up to 10% of pregnancies worldwide. Pregnancy hypertension is defined as systolic blood pressure (BP) equal to or greater than 140 mm Hg or a diastolic BP equal to or greater than 90 mm Hg, usually on the basis of measurements in office/clinic settings using various BP devices and BP thresholds that correspond to 2SDs above the mean BP throughout pregnancy. [1] [2] [3] Hypertensive disorders of pregnancy (HDPs) are classified into 3 primary types: (1) chronic hypertension diagnosed before pregnancy or before 20 weeks' gestation, (2) gestational hypertension diagnosed at equal to or greater than 20 weeks, or (3) preeclampsia, defined restrictively (and historically) as gestational hypertension with proteinuria or broadly as gestational hypertension with either proteinuria or an end-organ manifestation consistent with preeclampsia (Table 1) . 4, 5 There is widespread agreement on definitions other than for preeclampsia. 7 Preeclampsia is in the differential diagnosis of any hypertension from 20 weeks' gestation. First, up to 25% of women with chronic hypertension may develop superimposed preeclampsia and up to 35% with gestational hypertension (especially with onset at <34 weeks) may progress to preeclampsia. 8, 9 Second, preeclampsia is the HDP associated with the highest risk of complications, involving virtually any organ system to effect adverse outcomes through endothelial cell dysfunction and the hypertension itself. Finally, preeclampsia management is more than solely antihypertensive therapy (Table 1) , 5 mandating close interspecialty collaboration. 4 HDPs, especially preeclampsia, are associated with increased maternal and perinatal risks. Antihypertensive treatment of elevated BP, in the range of 140 to 159/90 to 109 mm Hg and to a target of 85 mm Hg diastolic, is associated with maternal benefit without increasing perinatal risk. 10 This approach applies to all HDPs and gestational age at presentation with hypertension. Of note, BP values equal to or greater than 160/110 mm Hg, regardless of the HDP, constitute a medical urgency requiring antihypertensive therapy 4, 7 ; more resourced settings are focused on determining the best initial treatment, bundling antihypertensive therapy with other aspects of management.
This review focuses on antihypertensive therapy for HDPs as a specific strategy within broader management that includes preeclampsia prevention in women with chronic hypertension and preeclampsia management. 5 
CLINICAL NEEDS IN THIS FIELD
Accurate Measurement of BP Blood pressure measurement techniques are the same in and outside pregnancy, including positioning and correct cuff size. 11 However, the choice of the BP device used is context sensitive.
The general withdrawal of mercury sphygmomanometers has left maternity care providers (eg, obstetricians, midwives, and nurses) with the choice of using aneroid or automated devices. (An accurate liquid crystal sphygmomanometer has been developed, but
is not yet widely available.) 12 Up to 50% of aneroid devices give inaccurate BP readings greater than 10 mm Hg through failure to maintain 6-monthly calibration and resultant calibration drift, whereas the same error occurs in only 10% of mercury devices. 13 Also, many automated devices are inaccurate in pregnancy and most are inaccurate in preeclampsia 14 don average, underreading by 5 mm Hg in systolic and diastolic, although there is wide variation. 15 A list of validated devices is 7 available online 16 ; to date, few have been validated for use in pregnancy or preeclampsia specifically.
Out-of-office measurements, particularly self-measurements at home, should play a key role in the diagnosis of hypertension in pregnancy as in nonpregnancy; however, self-measurement is largely driven by patient interest. The widespread, largely unregulated, use of personal devices is a major challenge for maternity care (as discussed below).
Agreed-Upon Classification of HDPs
There is widespread consensus that both systolic and diastolic BP should be included in the definition of hypertension in pregnancy, although a few societies use only the diastolic criterion. 7 The International Society for the Study of Hypertension in Pregnancy (ISSHP) has emphasized the need to repeat BP measurement over a few hours to confirm hypertension, or in 15 minutes if BP is severely elevated (ie, systolic BP !160 mm Hg or diastolic BP !110 mm Hg). By nonpregnancy standards, defining severe hypertension from a systolic BP of 160 mm Hg is low. This threshold was established on the basis of risk identified in an influential case series of women with stroke in pregnancy. 17 It is unclear whether pregnant women with hypertension are more susceptible to stroke because hypertension can develop quickly or because of the endothelial dysfunction of preeclampsia, but it is clear that autoregulation and BP level are not closely related. 18 The ISSHP classifies HDPs into groups depending on when in pregnancy elevated BP is documented, whether it is persistent, and whether there are features suggestive of preeclampsia ( Table 2 ). The ISSHP guidelines differ from some national guidelines by formally recognizing white coat, masked, and transient hypertension as distinct entities, and defining preeclampsia broadly.
The internal medicine community is familiar with white coat hypertension, and it should be managed in a similar way as outside pregnancy, relying on out-of-office measurements to guide antihypertensive therapy when women are outpatients. However, when women become inpatients (including for labor and delivery), clinicians have no choice but to treat severely elevated BP measurements taken in the hospital. Although the medical community should also be familiar with masked hypertension and would seek out-of-office BP measurement in the face of unexplained chronic kidney disease, for example, maternity care providers are unlikely to seek out-of-office BP measurements in the face of unexplained pregnancy complications that could be attributable to HDPs (eg, fetal growth restriction).
The ISSHP has emphasized the importance of transient hypertension, because it is not just elevated BP that was demonstrable because of poor measurement technique. Rather, transient gestational hypertension is associated with a 40% risk of developing true gestational hypertension or preeclampsia at some point in that pregnancy, mandating close follow-up. 4 Agreed-Upon Thresholds for Action For the mother, any hypertension is associated with more adverse outcomes in virtually any organ system, 19 from pulmonary edema and acute kidney injury to central nervous system complications, including stroke. 20, 21 Both End-organ involvement with preeclampsia includes, but is not limited to, neurological, respiratory, hepatic, and renal complications.
systolic and diastolic BP are important predictors of stroke, although variably associated. 17, 22 Also, HDPs remain the leading causes of maternal death globally.
For the fetus and newborn, HDPs are associated with stillbirth, neonatal death, and neonatal morbidity of various severities (depending on gestational age at birth and fetal growth).
Although studies have evaluated BP as a continuous measure, recent data from the Control of Hypertension in Pregnancy Study (CHIPS) trial of women with chronic or gestational hypertension indicate that the development of severe hypertension in women with a history nonsevere hypertension is associated with an increased risk for both mother and baby, independent of any concomitant preeclampsia. 10 Close Collaboration With Maternity Care Colleagues Standardized care and teamwork are particularly relevant during maternity care, a brief scenario by other medical standards (ie, maximum duration of 9 months of pregnancy and 6 weeks postpartum), and often delivered by many individuals with different skill sets. Standardization of complex care has been particularly topical within maternity services in the United States, given the upturn in maternal mortality, one of the leading causes of which is HDPs (alongside postpartum hemorrhage and obstetric sepsis). "Bundles" of complex care include management of severe hypertension. 23 The bundle goes beyond the "response" of antihypertensive therapy and both escalation measures for those unresponsive to standard treatment and postpartum follow-up to reporting and systems learning, readiness, and recognition and prevention.
SCIENTIFIC OVERVIEW OF PRECLINICAL AND CLINICAL STUDIES
Antihypertensive treatment of hypertension in pregnancy is guided by many randomized controlled trials (RCTs), although most have been small and many of low quality. 24, 25 These trials have enrolled women with various hypertensive disorders, although when women were enrolled at equal to or greater than 20 weeks' gestation, trials often did, or could, not distinguish between women with chronic hypertension and women with gestational hypertension or preeclampsia that, by definition, arose equal to or greater than 20 weeks. Thus, the global guideline consensus is that clinicians respond to absolute BP levels, regardless of the underlying HDP.
The implications of hypertension for the mother and baby depend both on the absolute level of BP and the rate at which it has risen. An abrupt increase in intraluminal pressure may result in mechanical distension of the cerebral vessel wall and structural damage, as, in cats, an abrupt (vs stepwise) increase in BP is associated with higher cerebrovascular permeability, a measure of vascular injury. 26 Antihypertensive Treatment of Severe Hypertension (BP of !160/110 mm Hg) Consistently, national and international guidance recommends that severe hypertension in pregnancy requires antihypertensive therapy to avoid acute cerebrovascular complications, particularly stroke. 7, 27 As in the nonpregnant state, severe hypertension unassociated with end-organ complication is usually a medical "urgency" and BP can be lowered over hours. In contrast, women with an end-organ complication(s), such as pulmonary edema or acute kidney injury, should have their BP lowered over a shorter time frame; to be conservative, women with headache and visual symptoms should be regarded as having end-organ complications. 20 As for nonpregnancy, the goal should be to lower BP to nonsevere levels (ie, <160/ 110 mm Hg) over hours without reducing it by more than 25% initially, with gradual lowering over hours thereafter. The fetoplacental unit, which does not autoregulate blood flow, is at risk of underperfusion during this time; appropriate fetal heart rate (FHR) monitoring should be instituted by the obstetrician or his or her designate. The intravascular volume depletion of preeclampsia can precipitate hypotension after the administration of short-acting antihypertensive agents.
Antihypertensive treatment of severe hypertension in pregnancy is guided by 52 RCTs (4588 women) of one short-acting antihypertensive vs another, usually parenterally administered (other than of oral nifedipine). [28] [29] [30] [31] [32] [33] [34] [35] Most published trials have compared parenteral hydralazine (usually 5 mg intravenously) with either calcium channel blockers (usually nifedipine 10 mg capsules orally) or parenteral labetalol (usually 20 mg intravenously), with repeat doses administered every 15 to 20 minutes to achieve BP control in at least 80% of women; in 10 trials, hydralazine was compared with drugs available only regionally or used infrequently. These dosing regimens are more conservative than those recommended by the American College of Obstetrics and Gynecology, which advises that clinicians administer the drugs in escalating doses to achieve the target BP. 36 Hydralazine may be a less effective antihypertensive and associated with more maternal adverse effects as compared with calcium channel blockers. Hydralazine may be a more effective antihypertensive but associated with more maternal hypotension and adverse effects as compared with parenteral labetalol. Most of the published hydralazine trials were included in a 2003 meta-analysis that compared hydralazine with all other shortacting antihypertensive agents taken together; hydralazine was associated with more adverse effects, including maternal hypotension, cesarean delivery, and adverse FHR effects. 29 It should be noted that in 2 hydralazine vs labetalol trials, parenteral labetalol was associated with more neonatal bradycardia (which required intervention in 1 of 6 affected babies in 1 trial).
Oral nifedipine and parenteral nicardipine appear to be similarly effective for BP control as parenteral labetalol. 34, 35 The nifedipine preparations that are appropriate for the treatment of severe hypertension are the capsule and the intermediate-acting (PA) tablet, 37 where available. Most authors did not specify whether nifedipine capsules were bitten (before swallowing), which may have a greater effect on BP. The 10 mg tablet may be associated with less maternal hypotension as compared with the 10 mg capsule when it is bitten/punctured. 38, 39 The 5 mg capsule may reduce the risk of a precipitous fall in BP. 39, 40 The effectiveness of nifedipine may be enhanced by concomitant vitamin D 41 or, postnatally, by concomitant furosemide. 42 As most women with severe hypertension in pregnancy have a hypertensive "urgency" that could be treated with oral agents, those agents (in addition to nifedipine discussed above) that lower BP over hours could be used. Although there are limited trial data evaluating this approach, 33, 43 oral labetalol (200 mg) has been used with good effect as part of a regional preeclampsia protocol in which treatment was successful in about half of women 44 or in comparison with oral nifedipine 33 ; this approach is recommended as the first-line therapy in the United Kingdom. 45 The results of an oral nifedipine (tablet), labetalol, and methyldopa trial will be reported in 2019 (ClinicalTrials.gov Identifier: NCT01912677). Although evidence is lacking, the administration of oral labetalol may also be useful before sending a woman to a hospital or arranging for her transport to the hospital for further management. 46 Drugs used infrequently, often for refractory hypertension during critical care, include clonidine and captopril, 31 nitroglycerin infusion, mini-bolus diazoxide, and sodium nitroprusside. 15 Sodium nitroprusside may cause fetal cyanide toxicity and stillbirth. 47 In summary, oral nifedipine, parenteral hydralazine, and parenteral labetalol are the most commonly studied antihypertensive agents for severe hypertension. As none is clearly superior, each is a reasonable choice, in doses listed in Table 2 . Some antihypertensive agents may be more or less appropriate depending on the associated medical conditions (such as poorly controlled asthma) or therapies (such as current treatment with full doses of labetalol).
The antihypertensive agents discussed here can be used with other medications. Nifedipine can be used together with magnesium sulfate as neuromuscular blockade in this setting is rare. 48 Magnesium sulfate is not an effective antihypertensive agent, although it can cause a transient mild decrease in BP. 49 Antihypertensive Therapy for Nonsevere Hypertension (BP of 140-159/90-109 mm Hg) Choice of Antihypertensive Agent in Early Pregnancy. Women with chronic hypertension will be treated with antihypertensive therapy before or in early pregnancy. Teratogenicity (ie, increased risk of major birth defects) and miscarriage risk should be considered and a decision made as to whether therapy should be discontinued or switched to another agent before pregnancy. Approximately half of pregnancies are unplanned; prescribers must consider the potential for pregnancy in all hypertensive women of reproductive age. If medication is to be discontinued or replaced before pregnancy, a further consideration is that conception may normally take up to 12 months and women older than 30 years suffer more subfertility. Therefore, women could be discontinuing their medication for some time; when renoprotection is the goal, timelines are suboptimal. In addition, women who have had an inadvertent first trimester exposure to antihypertensive therapy should be counseled about their risks.
Based on limited literature, it is considered that most antihypertensive agents do not increase the risk of major malformations above the baseline risk of 1% to 5% or the miscarriage rate of up to 20%. This concept of baseline risk is critical to communicate, as many women assume that their risk of early pregnancy problems is zero if they do not take the medication.
No antihypertensive medication is a proven human teratogen. Initial associations between angiotensin-converting enzyme (ACE) inhibitors and birth defects may have suffered from residual confounding. 50 Subsequent work has been variably reassuring. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (ARBs) have been associated with miscarriage (but not birth defects) in a prospective cohort study of 138 women as compared with both controls with hypertension and those with normal pregnancy; most women (79.8%) were exposed to ACE inhibitors (usually ramipril, lisinopril, or enalapril) rather than ARBs. 51 Angiotensin-converting enzyme inhibitors, ARBs, and other antihypertensive agents have been associated with teratogenicity in a metaanalysis of 5 controlled cohort studies (786 infants exposed to ACE inhibitors or ARBs, 1723 exposed to other antihypertensive agents, and 1,091,472 unexposed). 52 The UK clinical practice guidelines state that thiazides are teratogenic, but a reference was neither provided nor identified. 45 In summary, given the lack of consistent and high-quality literature, it is considered acceptable to continue antihypertensive agents, including ACE inhibitors and ARBs, until conception.
Threshold for Treatment in Ongoing
Pregnancy. There have long been concerns that antihypertensive treatment of nonsevere hypertension would decrease uteroplacental perfusion and fetal nutrition, leading to adverse fetal and newborn outcomes; an argument strengthened by a meta-regression analysis that associated greater antihypertensiveinduced falls in mean arterial pressure with decreased fetal growth velocity. 53 , 54 The CHIPS trial tested this hypothesis. 10 The CHIPS trial was a large definitive trial that provided evidence that nonsevere hypertension in pregnancy should be treated with antihypertensive therapy. 10 The CHIPS trial enrolled women with chronic (75%) or gestational (25%) hypertension, but superimposed preeclampsia developed in almost half of women, and they continued to receive BP treatment to which they were randomized for 2 subsequent weeks before delivery; therefore, it is reasonable to apply the results to all hypertensive pregnant women. Women with comorbidities such as renal disease and pregestational diabetes were excluded; "tight" control is advocated for them to reduce progression of renal disease and long-term cardiovascular risk as outside pregnancy.
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"Tight" BP control (target diastolic BP of 85 mm Hg) (vs "less tight" control, target diastolic BP of 100 mm Hg) achieved a significantly lower BP by 6/5 mm Hg with the use of a simple treatment algorithm for "tight" control that resulted in a mean BP of 133/85 mm Hg (P<.001); antihypertensive therapy was decreased if diastolic BP fell below 80 mm Hg, as frequently encountered with the midpregnancy fall in BP. 9 "Tight" (vs "less tight") control resulted in similar rates of the adverse perinatal outcomes and birth weight <10th percentile. However, "tight" (vs "less tight") control resulted in fewer adverse maternal outcomes of severe maternal hypertension, platelet count <100Â10 9 /L, and symptomatic elevated liver enzymes; there was no difference in serious maternal (end-organ) complications. Post hoc analyses determined that severe hypertension, independent of any associated preeclampsia, was a risk factor for complications for the mother and the baby and, in the "less tight" control arm specifically, severe hypertension was associated with more serious maternal complications. 55 Women in the "tight" (vs "less tight") control arm were equally satisfied with their care. 56 "Tight" control was likely to be cheaper by an average of CAD$6000, depending on lower neonatal care costs (P¼.07). 57 The results of the CHIPS trial are consistent with existing small trials that have shown that antihypertensive therapy (similar to "tight" control in CHIPS), compared with no treatment or placebo (similar to "less tight" control in CHIPS), decreases the risk of severe hypertension. 24 Women enrolled were usually without comorbidities, and various antihypertensive agents (initiated after the first trimester of pregnancy) were evaluated: methyldopa, labetalol, other pure b-blockers (acebutolol, mepindolol, metoprolol, pindolol, and propranolol), calcium channel blockers (isradipine, nicardipine, nifedipine, and verapamil), hydralazine, prazosin, and ketanserin. 24 This bodes well for women who have a contraindication to a particular medication, such as labetalol, because of poorly controlled asthma.
The 2018 ISSHP recommendations 4 endorse commencement of antihypertensive agents for persistent nonsevere hypertension well before BP reaches the 160/110 mm Hg mark, an approach that seeks to reduce the likelihood of developing severe maternal hypertension. An editorial pointed out that "to manage BP expectantly at less than 160/110 mm Hg but emergently at equal to or greater than 160/110 mm Hg is logically inconsistent"; the ISSHP supports this perspective. 58 However, the American Society for Maternal-Fetal Medicine is awaiting the results of the Chronic Hypertension and Pregnancy (CHAP) Project due in 2022 at the earliest (ClinicalTrials.gov Identifier: NCT02299414) before advising on the treatment of nonsevere chronic hypertension. The CHAP Project is enrolling women with chronic hypertension and randomizing them to treatment approaches similar to CHIPS. The CHAP Project will be powered to address whether "tight" control has additional benefits for the mother (ie, fewer serious maternal complications) or more adverse effects for the baby (ie, small for gestational age infants), but not whether there is a difference in pregnancy loss or morbidity. 59 With few exceptions, trials have initiated therapy with one antihypertensive agent. Clinicians are concerned about dropping BP too low, overriding knowledge that outside pregnancy, monotherapy will be insufficient to control BP if it is more than 20/10 mm Hg above the target BP. 11 In pregnancy, successful treatment of hypertension occurs in more than 70% of women who are primarily treated with one agent 24 ; the corresponding success rate is 30% to 50% outside pregnancy.
Choice of Antihypertensive Agent for BP Control. Angiotensin-converting enzyme inhibitors and ARBs should be discontinued once pregnancy is confirmed because of toxic effects, especially renal. If used before pregnancy for renoprotection, there is no reasonable alternative available in pregnancy; it is noteworthy that most renoprotection is afforded by "tight" control of BP by using any agent.
There is little to guide the choice of antihypertensive agent in pregnancy on the basis of comparative trials of one antihypertensive agent vs another. Meta-analysis and subsequent small trials have revealed no clear differences in maternal and perinatal outcomes. 24, [60] [61] [62] Compared with methyldopa, alternative drugs studied (ie, b-blockers and calcium channel blockers) may be more effective at reducing the risk of severe hypertension or preeclampsia. However, results for preeclampsia are inconsistent, and no firm conclusions can be drawn. b-Blockers, but not calcium channel blockers, may decrease the risk of preeclampsia compared with placebo/no therapy; however, when b-blockers and calcium channel blockers were compared directly, b-blockers did not decrease preeclampsia as would have been expected. Of note, in the CHIPS trial, women treated with methyldopa (vs labetalol) may have had better maternal and perinatal outcomes, although there may have been residual confounding. 63 Methyldopa, labetalol, and nifedipine, in doses listed in Table 2 , are the most commonly recommended antihypertensive agents in international practice guidelines, although oral labetalol is not widely available in low-and middle-income countries. 64 Vitamin D has been reported to enhance the effectiveness of nifedipine. 41 Thiazide diuretics can be considered for hypertensive women, but their use is limited to specific circumstances, such as medullary sponge kidney, despite concerns that they may inhibit the normal plasma volume expansion of pregnancy. Thiazide use after the first trimester did not adversely affect maternal or perinatal outcomes or prevent preeclampsia in RCTs. 65 Some antihypertensive agents may be best avoided in pregnancy, although not without controversy. Atenolol (in contrast to other, even cardioselective, b-blockers) may reduce fetal growth velocity, [66] [67] [68] [69] which is an inconsistent observation. 70 Prazosin may have been associated with more stillbirths in early severe preeclampsia. 71 Oral hydralazine is not recommended because of adverse effects when used alone. 72 There is an unsubstantiated belief that oral methyldopa may decrease fetal alertness and movement, or FHR variability and oral labetalol may decrease FHR and variability 73 ; prudently, changes in FHR or pattern should be ascribed to evolution of the underlying disease, not to prescribed antihypertensive(s).
Postpartum Antihypertensive Therapy. Blood pressure consistently rises from days 3 to 6 postpartum. Postpartum, hydralazine, labetalol, and nifedipine have been used for severe hypertension 74 ; all are appropriate during breastfeeding. Nifedipine may be more effective postnatally when administered with furosemide. 42 Some ACE inhibitors, acceptable during breastfeeding, can be reinitiated after delivery (such as enalapril and quinapril). Captopril is effective outside pregnancy but studied postpartum only in critical care. 6, 31, 33 Neonatologists have reservations in babies born early or small, but there are no reports of adverse effects. Only 2 antihypertensive agents are not recommended for use during breastfeeding: sodium nitroprusside, because toxic metabolites (thiocyanate and cyanide) may cross into breast milk; and oral clonidine, because of high serum drug levels in breastfed infants. 6 Information on drugs and breastfeeding is freely available in the LactMed database. 6 Long-Term Pediatric Neurodevelopmental Outcomes. The potential long-term developmental effects of antihypertensive therapy in pregnancy have been understudied. Most studies do not address important confounders of the relationship between outcomes and antihypertensive therapy, key among which is the type of HDP. Children of women with gestational hypertension or preeclampsia appear to have a relatively modest inconsistent increase in neurodevelopmental problems, such as inattention and externalizing behaviors (eg, aggression), fine or gross motor function, or verbal ability [75] [76] [77] [78] ; outcomes after chronic hypertension are unknown. Limited data from a few small RCTs are reassuring with regard to health or neurodevelopment at 12 to 18 months of age after nifedipine 79 or atenolol 80 or at 7.5 years after methyldopa.
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A controlled observational study presented reassuring data for labetalol (32 pregnancies). 82 Compared with women exposed to medications without known neurodevelopmental effects (N¼42), children with in utero methyldopa exposure (N¼25) had slightly lower intelligence quotient scores within the normal range, related to methyldopa treatment duration. 82 
CHALLENGES AND PITFALLS RELEVANT TO THE TOPIC Composite and Surrogate Outcomes
Of primary interest to clinicians and women is the effect of antihypertensive therapy on maternal, fetal, and newborn death and serious complications. For the mother, these include death, obstetric complications such as abruption, and end-organ complications (such as stroke). 19, 83 For the fetus and newborn, relevant outcomes are stillbirth, neonatal death, and life-threatening morbidity. Thankfully, these complications are individually uncommon or rare, but this situation poses a problem for researchers. Studying the effect of antihypertensive therapy on an individual complication (such as stroke) is not feasible, and even if it were, such a focus may reflect an arbitrary choice of outcome that does not reflect the spectrum of considerations at play. Also, the balance of benefit and risk may change with gestational age as do outcomes of relevance; for example, bronchopulmonary dysplasia is possible only if birth occurs before 32 weeks and hypoxicischemic encephalopathy is possible if birth occurs at term. Gestational age is also important for the mother, as the implications of severe hypertension as an outcome are different at 25 weeks in the setting of early severe preeclampsia, compared with term, as the gains from pregnancy prolongation vary.
As a response to these challenges, researchers have often studied surrogate outcomes (such as preeclampsia or preterm birth) or composites of rare complications. This challenge to evidence syntheses often results in few trials in subgroups of outcomes and uncertainty about whether the effects observed are influenced by reporting biases.
It is hoped that these challenges in outcome measurement will be addressed by the international movement toward standardization. Development of a core outcome data set in preeclampsia is nearing completion. 19 Unregulated Use of Home BP Monitoring Recently, home BP monitoring (HBPM) has gained popularity outside pregnancy in confirming hypertension as well as in improving BP monitoring, adherence to antihypertensive medication, and achievement of BP targets. 84 Compared with ambulatory BP monitoring, HBPM has modest diagnostic agreement, is similar in its ability to identify patients with a "white coat" effect and "masked" hypertension, and is economical and comfortable. Distinct advantages of HBPM in pregnancy are patient engagement, and the ease with which repeat measurements can be obtained, especially to rule out preeclampsia among women with either chronic or gestational hypertension. 85 Pregnant women and practitioners prefer HBPM to ambulatory BP monitoring. 86 Although HBPM is widely used by more than half of hypertensive women in some studies, 9 it is not widely appreciated by women or maternity care providers that what defines normal BP in the office (ie, !140/90 mm Hg) is higher than what defines normal BP at home (ie, !135/85 mm Hg), even in pregnancy. 4, 87 Also, practitioners do not usually advise women about available monitoring schedules, all of which involve duplicate measurements taken at least twice daily over several monitoring days. 11, 88 Many women take it upon themselves to measure their own BP. In addition, women are not necessarily educated about interpretation of the values recorded, including when and whom to call about BP values above a given threshold. 15 Nifedipine and Magnesium Sulfate Coadministration In women with preeclampsia in whom magnesium sulfate is indicated for eclampsia prevention or treatment, the risk of neuromuscular blockade (reversible with 10 g of intravenous calcium gluconate) with the contemporaneous use of nifedipine and magnesium sulfate is less than 1%. 48 
UNRESOLVED CLINICAL QUESTIONS
Nuanced Antihypertensive Therapy for Severe Hypertension and Nonsevere Hypertension Although antihypertensive therapy for severe hypertension has (with few exceptions) been with parenteral agents other than oral (usually short-acting) nifedipine, and therapy for nonsevere hypertension has been with oral agents, women with an HDP transition from one severity of hypertension to another. Severe hypertension and nonsevere hypertension are not separate clinical entities as are chronic hypertension and preeclampsia, for example. Clinical guidance has yet to address nuanced care reflecting clinical complexity or the large number of care providers. Direction about dose escalation and choice of multidrug antihypertensive treatment is lacking. Although the National Institute for Health and Care Excellence guidelines (United Kingdom) advise that oral labetalol be used as first-line therapy for hypertension of any severity, it may not be sensible to give a woman additional oral labetalol when she is already taking 1600 mg/d and presents with severe hypertension.
Personalized Antihypertensive Therapy
Outside pregnancy, different mechanisms underlie essential hypertension: either highrenin vasoconstriction or low renin, volume expansion. 89 Patients of black race tend to fit into the low-renin category. Although this knowledge influences choice of antihypertensive agent outside pregnancy, there is no similar guidance in pregnancy. Indeed, oral labetalol is considered an acceptable first-line agent for all pregnant women, even in settings in which the prevalence of women of black race is high (eg, the United Kingdom).
What about maternal hemodynamic assessment in hypertensive pregnant women? When assessed from the time of referral for hypertension (usually after 20 weeks' gestation), women whose BP was controlled (to <140/90 mm Hg) with labetalol monotherapy had higher heart rate and stroke volume (and were less likely to be of black race) 90 than did women requiring additional vasodilatory treatment with nifedipine. 91 Those requiring the vasodilatation also experienced more severe hypertension and had smaller babies. In 52 drug-naive pregnant women with various hypertensive disorders (38.5% chronic), when initial antihypertensive therapy was guided prospectively by hemodynamics, using initial nifedipine therapy when vascular resistance was high or women were of black race 92 and labetalol otherwise to achieve BP <140/ 90 mm Hg, the incidence of severe hypertension was low (3.8%) without compromising fetal growth. 93 Such a personalized approach based on hemodynamic assessment holds promise to optimize fetal growth for women receiving "tight" control of BP. However, more information is needed on feasibility, cost implications, and effectiveness.
The Patient Voice
Antihypertensive treatment has a clinically meaningful effect on maternal risk profiles, without adversely affecting the baby's risk profile or the woman's satisfaction with her care. However, the strength of recommendations is often weak and the quality of the evidence often low. Therefore, optimal decisions about BP control will depend on how each woman trades off (ie, values) her own vs her child's outcomes and how those values would change depending on the gestational age at which they would need to be made. At present, we lack the data to develop patient decision aids to help clinicians structure information and work with women to encourage them to evaluate all decision options and their consequences in accordance with their values without bias and to make a decision on the basis of those trade-offs. Also, we lack the data to measure value-weighted outcomes (which would be of particular relevance to composite outcomes). Lastly, we need our research to priority setting that involves input from all stakeholders, including women and their families, so that BP management research asks questions of relevance to women and measures outcomes that will inform their decision making.
CONCLUSION
Internationally, antenatal care is devoted in large part to the detection of preeclampsia by measurement of BP. The withdrawal of mercury sphygmomanometers has created a major challenge for accurate measurement of BP, as aneroid devices are less accurate and most automated devices underestimate BP in pregnancy and preeclampsia specifically. When elevated BP is detected, regardless of the HDP, antihypertensive therapy to achieve a diastolic BP of 85 mm Hg will decrease maternal risk without increasing perinatal risk. This antihypertensive therapy will of course be embedded in broader, multifaceted management of the mother and fetus.
Future work should focus on whether one antihypertensive drug offers advantages over another in general or for specific ethnic groups in pregnancy and whether hemodynamicguided antihypertensive therapy can optimize fetal growth and actually improve perinatal outcome.
Abbreviations and Acronyms: ACE = angiotensin-converting enzyme; ARB = angiotensin receptor blocker; BP = blood pressure; CHAP = Chronic Hypertension And Pregnancy; CHIPS = Control of Hypertension In Pregnancy Study; FHR = fetal heart rate; HBPM = home blood pressure monitoring; HDP = hypertensive disorder of pregnancy; ISSHP = International Society for the Study of Hypertension in Pregnancy; RCT = randomized controlled trial 
